Pivotal bioVenture Partners
Pivotal bioVenture Partners is a San Francisco-based venture capital firm investing in early stage biotechnology companies
Business Model: B2B
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Pivotal bioVenture Partners Information
Geographic Data
Address: 1700 Owens St Ste 595
City: San Francisco
State: CA
Zip: 94158
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$450M
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Pivotal bioVenture Partners is a $300 million life sciences venture capital fund established in 2017. They invest in privately held North American and European companies focused on innovative therapeutic products and platforms to address major unmet medical needs. They invest at all stages in a company’s evolution, from company creation through mid and late stage clinical development. Their team brings diverse experience in venture capital, company building, and drug discovery and development to the table in working with entrepreneurs to advance their businesses.
Contact Phone:
+14156971002
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2022 | Arkuda Therapeutics | Series B | 0 |
| 6/2018 | Stealth BioTherapeutics | Convertible Note | 0 |
| 2/2019 | Bolt | Series B | 54M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 1/2021 | Plexium | Series A | 35M |
| 11/2020 | Evommune | Seed Round | 12.5M |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 3/2023 | Oculis | Post-IPO Equity | 0 |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 4/2019 | Inozyme | Series A | 67.4M |
| 4/2020 | Rallybio | Series B | 0 |
| 1/2018 | Oculis | Series B | 20.5M |
| 5/2021 | Oculis | Series C | 0 |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 3/2017 | Vaxcyte | Series B | 60M |
| 3/2020 | Vaxcyte | Series D | 0 |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 3/2020 | Akouos | Series B | 105M |
| 9/2017 | Entasis Therapeutics | Series B | 31.9M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 9/2021 | Obsidian Therapeutics | Series B | 0 |
| 4/2020 | Avalyn Pharma | Series B | 35.5M |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 4/2021 | Exscientia | Series D | 225M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 9/2021 | Evommune | Series A | 83M |
| 4/2023 | Evommune | Series B | 50M |
| 2/2022 | Plexium | Series B | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 2/2022 | Plexium | Series B | 0 |
| 2/2022 | Arkuda Therapeutics | Series B | 0 |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 9/2021 | Obsidian Therapeutics | Series B | 0 |
| 9/2021 | Evommune | Series A | 0 |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 5/2021 | Oculis | Series C | 0 |
| 4/2021 | Exscientia | Series D | 0 |
| 1/2021 | Plexium | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
